553 results about "Lung fibrosis" patented technology

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-COV-2. Lung function stabilizes or is improved as a result of treatment.

The present disclosure provides methods of treating pulmonary fibrosis, the methods comprising administering taladegib to a subject in need thereof.

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.

The present disclosure provides methods of treating pulmonary fibrosis, the methods comprising administering taladegib to a subject in need thereof.

Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-COV-2. Lung function stabilizes or is improved as a result of treatment.

The present disclosure provides methods of treating pulmonary fibrosis, the methods comprising administering taladegib monotherapy as the main component to a subject in need thereof, as well as diagnostic criteria and markers establishing the progress of therapy.

The invention belongs to the technical field of medicines, and provides application of Nintedanib and a plant-derived cyclic peptide and radix pseudostellariae cyclic peptide B combined medicine in preparation of a medicine for treating pulmonary fibrosis, the Nintedanib and the plant-derived cyclic peptide and radix pseudostellariae cyclic peptide B combined medicine can play a synergistic effect, and the inhibition effect on the pulmonary fibrosis process is remarkably improved. The toxic and side effects of diarrhea and intestinal mucosa injury caused by nintedanib are reduced, and a good choice is provided for clinical treatment of pulmonary fibrosis.

The invention discloses a radionuclide labeled molecular probe for detecting collagen structure denaturation and a preparation method and application thereof, and relates to the technical field of biology. The structural general formula of the radionuclide labeled molecular probe disclosed by the invention is as follows: K (chelating agent-nuclide)-K-Linker-CHP, wherein K (chelating agent-nuclide) is a lysine residue labeled by a side chain amino coupling chelating agent and a radionuclide; the Linker is a connection joint; cHP is a collagen hybrid peptide with a polypeptide sequence of (GfO) n or (GPO) n. The probe has excellent definition and signal-to-noise ratio, not only can detect pancreatic ductal adenocarcinoma in a pancreatic cancer model, but also can sensitively detect precancerous lesions (such as pancreatic intraepithelial neoplasia lesions) of the pancreatic ductal adenocarcinoma and pulmonary fibrosis lesions in a bleomycin pulmonary fibrosis model. And the kit has important significance on early detection of pancreatic duct adenocarcinoma and reflection of dynamic change of ECM remodeling.

The invention provides an inhalable tanshinone IIA lipid nanocrystal as well as a preparation method and application thereof, and the inhalable tanshinone IIA lipid nanocrystal is mainly formed by entrapping tanshinone IIA by using dipalmitoyl phosphatidylcholine DPPC and dipalmitoyl phosphatidyl ethanolamine DPPE as mixed phospholipids in the presence of a stabilizer. Compared with the prior art, the inhalable tanshinone IIA lipid nanocrystal disclosed by the invention has the advantages that by improving the physicochemical property and drug release behavior of TA, the lung retention volume of TA after aerosol inhalation is obviously increased, the retention time of TA in the lung is prolonged, and the risk of toxic and side effects caused by whole-body escape of drugs is reduced; the treatment effect on idiopathic pulmonary fibrosis is improved, and the compliance of a patient is improved.

The present invention discloses the application of a 1,7-dihydro-6H-purin-6-one compound in the preparation of an anti-pulmonary fibrosis drug, which relates to the technical field of biomedicine. The application of the 1,7-dihydro-6H-purin-6-one compound of the present invention in the preparation of an anti-pulmonary fibrosis drug detects the anti-pulmonary fibrosis pharmacological activity of the 1,7-dihydro-6H-purin-6-one compound after structural modification and transformation, tests the pharmacological activity of this type of compound in a variety of animal disease models, and provides data on the activity of preventing and treating different types of pulmonary fibrosis, confirming that they all have good activity, and the effect is significantly better than the clinically commonly used positive drug nintedanib, and the effect is also better than hypoxanthine analogs A, B, and C. The application of the 1,7-dihydro-6H-purin-6-one compound of the present invention in the preparation of an anti-pulmonary fibrosis drug can provide a new skeleton for the screening of new compounds for the preparation of anti-pulmonary fibrosis drugs, and lay a theoretical foundation for the development of new lead compounds.

The invention belongs to the technical field of medicines, and particularly relates to a secondary ginsenoside composition and application thereof in prevention and treatment of pulmonary fibrosis and acute lung injury. The secondary ginsenoside composition is prepared from any two or more components selected from the following components: (20S)-Rg2, (20S)-Rh1, (20R)-Rg2, (20R)-Rh1, Rg6, F4, Rk3 and Rh4; (20S)-Rg3, (20R)-Rg3, Rk1, Rg5, (20S)-Rh2, (20R)-Rh2, Rk2 and Rh3 are selected from the group consisting of (20S)-Rg3, (20R)-Rg3, Rk1 and Rg5. The medicine effect of the secondary ginsenoside composition provided by the invention on the aspects of preventing and treating pulmonary fibrosis and acute lung injury is obviously superior to that of a primary ginsenoside composition and secondary saponin Rg5 and Rg3 monomer components. Meanwhile, the secondary ginsenoside composition is more easily absorbed by intestinal tracts than a primary ginsenoside composition, and is slightly influenced by individual differences of intestinal flora. Compared with a secondary saponin monomer component, the compound is easier to prepare, lower in production cost and safer and more efficient compared with existing commercially available drugs.

The invention relates to a nano preparation for delivering antibiotics based on plant extracts and application of the nano preparation, and belongs to the technical field of nano preparations. In order to solve the problems of low bioavailability and low action efficiency of oral administration or intravenous injection of antibiotics in the lung disease treatment process, the invention provides a nano preparation for delivering antibiotics based on plant extracts. The mass volume ratio of the antibiotics to the plant extract in the nano preparation is (1-10) mg: (20-100) mu L. The nano preparation disclosed by the invention can obviously inhibit the migration of fibroblasts, has an obvious bacteriostatic effect and can reduce the density of microorganisms in lungs; positive charges carried by the material are combined with negative charges on the surface of a bacterial cell membrane, transmembrane substance transfer on the bacterial cell membrane is affected, bacterial metabolism and reproduction are affected, adjustment of pulmonary symbiotic bacteria is better achieved, and the pulmonary fibrosis progress can be relieved. The nano preparation has the advantages of small toxic and side effects, good patient compliance, high encapsulation efficiency and the like.

Various processes, algorithms, and systems are provided herein for assisting physicians in distinguishing among related diseases, such as distinguishing connective tissue associated interstitial lung disease from idiopathic pulmonary fibrosis. Methods for generating such processes, algorithms, and systems are also disclosed. In some embodiments, a preliminary diagnosis of a set of possible diseases is obtained, along with protein count information from a patient's blood sample. Additional, patient-specific information (e.g., age, sex, etc.) may also be obtained. The data is processed by a trained machine learning algorithm, to output a differential diagnosis of which of the set of possible diseases is present for that patient. Based on the diagnosis, a treatment course can be selected, and further information can be tracked regarding the patient's outcome.

The invention belongs to the field of pharmacy, and relates to a medicine for treating pulmonary fibrosis, in particular to application of an anti-Gremlin1 antibody to preparation of a medicine for preventing and treating pulmonary fibrosis. The Gremlin1 antibody disclosed by the invention can be applied to prevention and treatment of pulmonary fibrosis, effectively improves bleomycin (BLM)-induced pulmonary fibrosis lesions of mice and improves the survival rate of the mice. Compared with a BLM group, the mouse inspiration capacity (IC) and the lung static compliance (CRS) treated by the Gremlin1 antibody are remarkably improved, the hydroxyproline content in lung tissue is remarkably reduced, and compared with the BLM group, the Ashcroft score, the collagen deposition area in Masson three-color dyeing and the Sirius red dyeing area of an antibody intervention group are remarkably reduced, and the proportion of activated endothelial cells and the proportion of transition-state epithelial cells are remarkably reduced. Therefore, the Gremlin1 antibody can be used for preparing the medicine for preventing and / or treating the pulmonary fibrosis.

The present disclosure provides biomarkers associated with caveolin-1 peptide therapy in subjects with interstitial lung disease. In particular, the present disclosure describes biomarkers such as MYDGF, soluble RAGE, pSMAD2 / 3, and PDGFRβ associated with caveolin-1 peptide therapy in subjects with idiopathic pulmonary fibrosis. These biomarkers could be used to determine efficacy, monitoring, and optimal dosing of caveolin-1 peptide therapy in subjects with interstitial lung disease.

Disclosed is a method for ameliorating, preventing or treating systemic sclerosis and pulmonary fibrosis, including administering to a subject in need thereof a composition containing Bifidobacterium longum RAPO (KCTC13773BP) as an active ingredient. The composition controls infiltration and inflammatory response of inflammatory monocytes and macrophages, and facilitates an increase in short-chain fatty acid producing microorganisms, thus being effective in ameliorating, preventing or treating systemic sclerosis and pulmonary fibrosis.

Provided herein are modulators of a long noncoding transcript, pharmaceutical compositions comprising the modulator, and kits comprising the modulator. Also provided herein are methods of modulating a long noncoding transcript in a subject in need thereof. Further provided here are methods of preventing, alleviating, or treating pulmonary fibrosis or inflammation induced or associated with ARDS in a subject in need thereof.

The present disclosure provides methods of treating pulmonary fibrosis, the methods comprising administering taladegib to a subject in need thereof.

The invention discloses an aza-four-membered ring connected pyrazolopyridine compound or pharmaceutically acceptable salt and application thereof, and the compound with the structure can be used as a novel high-selectivity PDE10A inhibitor for treating peripheral tissue diseases such as cardiac hypertrophy and cardiac dysfunction (heart failure), diabetes, hypertension, renal function impairment and renal fibrosis. Lung inflammation and pulmonary fibrosis, immune regulation disorder and cancers (colon cancer, ovarian cancer and lung cancer). Through strategies in two aspects, the inhibition effect of the compound on a PDE10A high-selectivity inhibitor is reduced while the inhibition effect of the compound on a central nervous system is reduced. Firstly, in the aspect of molecular structure modification, the structure of the pyrazolopyridine compound connected with the aza-four-membered ring is optimized, for example, the polar surface area of molecules is increased by increasing the proportion of the number of N, O and S atoms in the molecular structure, and the fat solubility is reduced; and hydrophilic groups are introduced to increase water solubility and the like, so that the permeability of the compound to the blood brain barrier BBB is reduced. And 2, targeted drug delivery of lung tissues is realized by means of a pharmaceutical preparation.

The invention discloses application of isovitexin in treatment of pulmonary fibrosis, and belongs to the technical field of medicines. The isovitexin with different concentrations is used for treating a pulmonary fibrosis model, detecting pulmonary fibrosis markers and various ferroptosis related markers, and exploring the influence of the isovitexin on the pulmonary fibrosis animal model and how the isovitexin affects the growth of pulmonary fibrosis cells. Finally, a conclusion is drawn: (1) the pulmonary fibrosis is treated by the isovitexin, so that ferroptosis of cells is promoted, and collagen deposition is reduced; and (2) isovitexin is used, so that the progress of pulmonary fibrosis can be inhibited.

The invention relates to application of hydroxynidone to preparation of a medicine for preventing and / or treating radiation-induced pulmonary fibrosis. Pharmacological experiments prove that the hydroxynidone has a definite resisting effect on radioactive rat lung injury including early inflammatory exudation and pulmonary interstitial fibroblast hyperplasia, and can obviously reduce pulmonary alveolar inflammatory cell exudation and reduce the content of TGF beta 1 in inflammatory exudate; the medium and large doses have the effect of delaying the development of interstitial pneumonia towards pulmonary fibrosis; the lesion degrees of the small, medium and large dosage groups are obviously reduced and are in a dose-effect relationship.

Provided herein are compositions comprising caveolin-1 (Cav-1) peptides. Further provided are methods of using the Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis / marijuana, nicotine, and activities including gambling.Compounds are of general formulawith substituents as defined herein.

A system and method for computing a lung fibrosis metric are described. The system has an input interface to receive initial lung imaging data for the patient, a trained neural network lung segmentation model to generate lung segmentation data from the initial lung imaging data, a fibrosis model pre-processor to apply the lung segmentation data to the lung imaging data to produce modified lung imaging data, a trained neural network lung fibrosis model to generate fibrosis segmentation data from the modified lung imaging data, a fibrosis model post-processor to process the fibrosis segmentation data in combination with the lung segmentation data to generate labelled voxel data, a fibrosis metric processor to use the labelled voxel data to compute a fibrosis volume metric for the patient, and an output interface to provide the fibrosis volume metric as the lung fibrosis metric for the patient.

The invention discloses a tetrandrine ferulate and its application in the preparation of a medicament for treating pulmonary fibrosis. The pharmacological effects of tetrandrine and ferulic acid, as well as those after salification, are studied. It is found that both have an anti-pulmonary fibrosis effect, and the two can be used in combination to synergistically exert a more excellent anti-pulmonary fibrosis efficacy. At the same time, the solubility of tetrandrine can also be increased. This has not been reported in existing literature. The tetrandrine ferulate of the present invention has lower cytotoxicity, and the cell viability of normal human liver cells LO-2 and human embryonic fibroblasts MRC-5 is higher than that of tetrandrine, which alleviates the burden of liver and lungs to a certain extent and has good safety.

The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.

The invention relates to the technical field of biological medicines, in particular to application of 1, 3-butanediol in treatment of idiopathic pulmonary fibrosis. 1, 3-butanediol inhibits pulmonary fibrosis and promotes lung function recovery by regulating AT2 cell proliferation, inhibiting differentiation of fibroblasts to myofibroblasts, inhibiting polarization of macrophages to M2 macrophages and regulating lipid metabolism.

The invention belongs to the field of biological agents, and particularly relates to application of polypeptide Angio-3 in preparation of medicine for treating pulmonary fibrosis. The invention provides a polypeptide Angio-3 with an effect of improving pulmonary fibrosis diseases, the polypeptide Angio-3 can effectively inhibit activation of lung fibroblasts and deposition of extracellular matrixes in an in-vitro cell model induced by TGF-beta1, and the polypeptide Angio-3 has no obvious toxic effect on alveolar epithelial cells and fibroblasts; in a SiO2 induced silicosis model, Angio-3 can be used for inhibiting alveolar epithelial cell fibrosis and epithelial-mesenchymal transition. The invention provides application of Angio-3 in preparation of drugs for treating pulmonary fibrosis diseases, and provides effective drugs and new ideas for clinical anti-pulmonary fibrosis treatment.

Provided herein are compositions comprising caveolin-1 (Cav-1) peptides. Further provided are methods of using the Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.